

### Literature hPSA

1. Carol D. Cheli, Martin Marcus, Jack Levine, Zegi Zhou, Peter H. Anderson, Daniel D. Bankson, Jay Bock, Sharon Bodin, Carlotta Eisen, Marilyn Senior, Morton K. Schwartz, Kwok K. Yeung, and W. Jeffrey Allard *Variation in Quantitation of Prostate-specific Antigen in Reference Material: Differences in commercial Immunoassays*, *Clinical Chem.* 44, No. 7, 1998
2. Sheila A.R: Kort, Frans Martens, Hilde Vanpoucke, Hans L. Van Duijnhoveb, and Marinus A. Blankenstein *Comparison of 6 Automated assays for Total and Free Prostate-Specific Antigen with Special reference to Their Reactivity toward the WHO 96/670 Reference Preparation*, *Clinical Chem.* 52:8 1568-1574 (2006)
3. Brian Rafferty, Peter Rigsby, Matthew Rose, Thomas Stamey, and Rose Gaines Das: *Reference Reagents for Prostate-Specific Antigen (PSA): Establishment of the First International Standards for Free PSA and PSA (90:10)*, *Clinical Chem* 46:9 1310-1317 (2000)
4. Stephan C(1), Bangma C, Vignati G, Bartsch G, Lein M, Jung K, Philippe M, Semjonow A, Catalona WJ. *20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers*. *Int J Biol Markers.* 2009 Apr-Jun;24(2):65-9.
5. Hanif M, Zaidi P, Kamal S, Idrees S, Rasool SA. *Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients*. *J Pak Med Assoc.* 2007 May;57(5):248-51.
6. Bartos V, Stern P, Zavada M, Gartnarova M, Safarcik K. *Effect of the preparation method of control samples on external quality assessment results of PSA testing*. *Anticancer Res.* 2003 Jan-Feb;23(1A):479-84.
7. Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A. *Total and free PSA: a methodical and clinical evaluation of five assays*. *Anticancer Res.* 1997 Nov-Dec;17(6D):4759-65.
8. Cevik I, Türkeri LN, Ozveri H, Ilker Y, Akdaş A. *Short-term effect of digital rectal examination on serum prostate-specific antigen levels. A prospective study*. *Eur Urol.* 1996;29(4):403-6.
9. Ooi DS, Escares EA. *"High-dose hook effect" in IRMA-Count PSA assay of prostate-specific antigen*. *Clin Chem.* 1991 May;37(5):771-2.
10. Lindstedt G, Jacobsson A, Lundberg PA, Hedelin H, Pettersson S, Unsgaard B. *Determination of prostate-specific antigen in serum by immunoradiometric assay*. *Clin Chem.* 1990 Jan;36(1):53-8.
11. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brüner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry. *National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers*. *Clin Chem.* 2008 Dec;54(12):e11-79.
12. Greene KL(1), Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association. *Prostate specific antigen best practice statement: 2009 update*. *J Urol.* 2013 Jan;189(1 Suppl):S2-S11